Understanding the Market | FUSEN PHARM surged nearly 74% during the session as Enzalutamide soft capsules were approved for market launch, and Metformin and Ertugliflozin tablets are expected to be selected for national centralized procurement

Zhitong
2025.10.31 02:34
portai
I'm PortAI, I can summarize articles.

FUSEN PHARM's stock price surged nearly 74% during the trading session, and as of the time of writing, it has risen by 49.28%, trading at HKD 1.03, with a transaction volume of HKD 10.3715 million. In terms of news, FUSEN PHARM announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of the People's Republic of China for the listing application of "Enzalutamide Soft Capsules," which is approved for the treatment of the following diseases: adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis; and adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms and have not received chemotherapy after failure of androgen deprivation therapy (ADT). FUSEN PHARM also announced that its product Metformin and Ertugliflozin Tablets (I) (500mg Metformin Hydrochloride and 5mg Ertugliflozin) is expected to win a bid in the recently announced results of the 11th batch of national centralized drug procurement in China. It is reported that FUSEN PHARM announced in September this year that the listing application for its developed "Metformin and Ertugliflozin Tablets (I)" has been approved by the National Medical Products Administration of China

According to Zhitong Finance APP, FUSEN PHARM (01652) rose nearly 74% during the trading session, and as of the time of writing, it has increased by 49.28%, trading at HKD 1.03, with a transaction volume of HKD 10.3715 million.

On the news front, FUSEN PHARM announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of the People's Republic of China for the listing application of "Enzalutamide Soft Capsules." The approval is for the treatment of the following diseases: adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastatic progression; and adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms and have not received chemotherapy after failure of androgen deprivation therapy (ADT).

FUSEN PHARM also announced that its product Metformin and Ertugliflozin Tablets (I) (500mg Metformin Hydrochloride and 5mg Ertugliflozin) is expected to win the bid in the recently announced results of the 11th batch of national centralized drug procurement in China. It is reported that FUSEN PHARM announced in September this year that the listing application for its developed "Metformin and Ertugliflozin Tablets (I)" has been approved by the National Medical Products Administration of China

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer